Search results for "C25"

showing 10 items of 566 documents

Impact of Extracellular Acidity on the Activity of P-glycoprotein and the Cytotoxicity of Chemotherapeutic Drugs

2006

AbstractThe expression and activity of P-glycoprotein (pGP) play a role in the multidrug resistance of tumors. Because solid-growing tumors often show pronounced hypoxia or extracellular acidosis, this study attempted to analyze the impact of an acidic environment on the expression and activity of pGP and on the cytotoxicity of chemotherapeutic agents. For this, prostate carcinoma cells were exposed to an acidic extracellular environment (pH 6.6) for up to 24 hours. pGP activity was more than doubled after 3 to 6 hours of incubation in acidic medium, whereas cellular pGP expression remained constant, indicating that increased transport rate is the result of functional modulation. In paralle…

Cancer ResearchDaunorubicinPharmacologyP-glycoproteinlcsh:RC254-282Calcium in biologyExtracellularmedicinepolycyclic compoundsintracellular Ca2+ concentrationCytotoxicityacidityProtein kinase CP-glycoproteinbiologyintegumentary systemChemistrychemotoxicitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscarbohydrates (lipids)BiochemistryCell culturebiology.proteinIntracellularmedicine.drugprotein kinase CNeoplasia
researchProduct

Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30

2010

Abstract Background To clarify the immunological alterations leading to classical Kaposi sarcoma (cKS) among people infected with KS-associated herpesvirus (KSHV). Methods In a population-based study of 119 cKS cases, 105 KSHV-seropositive controls, and 155 KSHV-seronegative controls, we quantified plasma soluble cluster of differentiation (sCD) levels and antibodies against Epstein-Barr virus nuclear antigen-1 (anti-EBNA-1) and viral capsid antigen (anti-VCA). Differences between groups in prevalence of low-tertile anti-EBNA-1 and high-tertile anti-VCA were compared by logistic regression. Continuous levels between groups and by presence of cKS co-factors among controls were compared by li…

Cancer ResearchEpidemiologyPopulationmedicine.disease_causeSettore MED/42 - Igiene Generale E Applicatalcsh:RC254-282Viruslcsh:Infectious and parasitic diseasesDiabetes mellitusmedicinelcsh:RC109-216educationeducation.field_of_studyEpstein-Barr virus antibodiebiologyCluster of differentiationbusiness.industryKaposi sarcomasCD26 sCD23 and sCD30lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseEpstein–Barr virusInfectious DiseasesOncologyImmunologyKaposi sarcoma; Epstein-Barr virus antibodies; sCD26 sCD23 and sCD30biology.proteinSarcomaCortisoneAntibodybusinessmedicine.drugResearch ArticleInfectious Agents and Cancer
researchProduct

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

2015

Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the tubulin polymer and stabilize microtubules, while the latter bind to the tubulin dimers and destabilize microtubules. Alteration of tubulin-microtubule equilibrium determines th…

Cancer ResearchEpothilonesSettore MED/06 - Oncologia MedicaOmbrabulin2734Antineoplastic AgentsReview ArticleMicrotubulesPathology and Forensic Medicinechemistry.chemical_compoundMicrotubuleNeoplasmsHumansRC254-282QH573-671biologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancer Research; Molecular Medicine; 2734; Cell BiologyCell BiologyGeneral MedicineDiscodermolideCell cycleCell biologySpindle apparatusTubulinchemistrybiology.proteinMolecular MedicineCytologyIntracellularAnalytical Cellular Pathology
researchProduct

Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tum…

2021

Simple Summary Variable domains of heavy chain only antibodies are small proteins that can be used for tumor imaging and therapy upon conjugation of functional groups. As frequently used random conjugation techniques can decrease binding to the target of interest, site-specific conjugation of these functional groups is preferred. Here, we optimized site-specific conjugation of both a chelator for binding of a radiometal and a photosensitizer to epidermal growth factor receptor (EGFR) binding VHH 7D12. We characterized this dual-labeled VHH for nuclear imaging and targeted photodynamic therapy of EGFR-expressing tumors. Abstract Variable domains of heavy chain only antibodies (VHHs) are valu…

Cancer ResearchFluorescence-lifetime imaging microscopyBiodistribution[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedia_common.quotation_subjectmedicine.medical_treatmentPhotodynamic therapyvariable domain of heavy chain only antibodies (VHH); site-specific conjugation; dual-labeling; nuclear imaging; photodynamic therapy[SDV.CAN]Life Sciences [q-bio]/Cancer[CHIM.THER]Chemical Sciences/Medicinal Chemistrylcsh:RC254-282Article030218 nuclear medicine & medical imaging03 medical and health sciencesTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterIn vivoduallabelingmedicineTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]PhotosensitizerInternalizationmedia_commonnuclear imagingChemistrysite-specific conjugationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncologyphotodynamic therapy030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]dual-labelingBiophysicsvariable domain of heavy chain only antibodies (VHH)A431 cellsEx vivoCancers
researchProduct

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

2020

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg

Cancer ResearchGastroenterologypimasertiblaw.invention0302 clinical medicineRandomized controlled triallawClinical endpoint030212 general & internal medicineMalignant melanomaHazard ratioProgression-free survivalSciences bio-médicales et agricoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthDacarbazineOncology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030220 oncology & carcinogenesismedicine.symptomPimasertibmedicine.drugQuality of lifemedicine.medical_specialtyNauseaDacarbazinemalignant melanomadacarbazine[SDV.CAN]Life Sciences [q-bio]/CancerN-(2 3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamideNeutropeniaN-(23-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamidelcsh:RC254-282Article03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicinemedicineProgression-free survivalAdverse effectbusiness.industry[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.diseaseadverse eventsCancérologiequality of lifeAdverse events[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologybusinessprogression-free survival[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Aberrations of Genomic Imprinting in Glioblastoma Formation

2021

In human glioblastoma (GBM), the presence of a small population of cells with stem cell characteristics, the glioma stem cells (GSCs), has been described. These cells have GBM potential and are responsible for the origin of the tumors. However, whether GSCs originate from normal neural stem cells (NSCs) as a consequence of genetic and epigenetic changes and/or dedifferentiation from somatic cells remains to be investigated. Genomic imprinting is an epigenetic marking process that causes genes to be expressed depending on their parental origin. The dysregulation of the imprinting pattern or the loss of genomic imprinting (LOI) have been described in different tumors including GBM, being one …

Cancer ResearchGenomic imprintingSomatic cellSubventricular zonePopulationReviewBiologylcsh:RC254-282MethylationGliomamedicineEpigeneticsImprinting (psychology)educationneural stem cellsNeural stem cellseducation.field_of_studyglioblastomasubventricular zonelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNeural stem cellgenomic imprintingnervous system diseasesOncologyCancer researchmethylationStem cellGenomic imprintingGlioblastoma
researchProduct

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

2021

Simple Summary Intrahepatic cholangiocarcinoma is a rare disease with increasing incidence and mortality still characterized by an insufficient clinical outcome. Growing attention has recently surrounded this disease, and liver transplantation has emerged as a novel curative treatment for cholangiocarcinoma, along with a better understanding of genetic alterations potentially capable of driving tumorigenesis. The aim of this paper is to present a clinical description of our case series of patients affected by intrahepatic cholangiocarcinoma and by mixed forms of hepatocellular and cholangiocellular carcinoma, together with a genomic profiling of mutations occurring in a panel of genes relev…

Cancer ResearchLiver tumorliver transplantationbusiness.industrymedicine.medical_treatmentWnt signaling pathwayCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensLiver transplantationmedicine.diseasemedicine.disease_causeArticlenext-generation sequencing.Oncologyintrahepatic cholangiocarcinomamedicineCancer researchnext-generation sequencingKRASCarcinogenesisbusinessPI3K/AKT/mTOR pathwayIntrahepatic CholangiocarcinomaRC254-282intrahepatic cholangiocarcinoma; liver transplantation; next-generation sequencingCancers
researchProduct

XPO1E571K Mutation Modifies Exportin 1 Localisation and Interactome in B-cell Lymphoma

2020

The XPO1 gene encodes exportin 1 (XPO1) that controls the nuclear export of cargo proteins and RNAs. Almost 25% of primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) cases harboured a recurrent XPO1 point mutation (NM_003400, chr2:g61718472C&gt

Cancer ResearchMutantXPO1/CRM1[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]CRISPR–Cas9[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]lcsh:RC254-282Article03 medical and health sciencesXPO10302 clinical medicineproteomics[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesExportin-1hemic and lymphatic diseases[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]medicine[SDV.BC.BC] Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]B-cell lymphomaNuclear export signalproximity ligation assay030304 developmental biology0303 health sciencesimportin β1ChemistryB-cell lymphomaPoint mutationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMolecular biologynuclear importindirect immunofluorescenceOncology030220 oncology & carcinogenesisMutation (genetic algorithm)nuclear exportNuclear transportCRISPR-Cas9
researchProduct

Algorithmically deduced FREM2 molecular pathway is a potent grade and survival biomarker of human gliomas

2021

Gliomas are the most common malignant brain tumors with high mortality rates. Recently we showed that the FREM2 gene has a role in glioblastoma progression. Here we reconstructed the FREM2 molecular pathway using the human interactome model. We assessed the biomarker capacity of FREM2 expression and its pathway as the overall survival (OS) and progression-free survival (PFS) biomarkers. To this end, we used three literature and one experimental RNA sequencing datasets collectively covering 566 glioblastomas (GBM) and 1097 low-grade gliomas (LGG). The activation level of deduced FREM2 pathway showed strong biomarker characteristics and significantly outperformed the FREM2 expression level it…

Cancer ResearchMutantnapoved preživetjaBiologyTranscriptometranscriptomicsGliomagliomagliommedicineGeneRC254-282udc:616-006glioblastomWild typeglioblastomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssurvival prognosisMolecular pathway<i>FREM2</i>medicine.diseasenervous system diseasesOncologyCancer researchBiomarker (medicine)algorithmically deduced molecular pathwayFREM2Glioblastoma
researchProduct

Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm

2021

Simple Summary For the first time, neuronal features are described in blastic plasmacytoid dendritic cell neoplasm (BPDCN) by a complex array of molecular techniques, including microRNA and gene expression profiling, RNA and Chromatin immunoprecipitation sequencing, and immunohistochemistry. The discovery of unexpected neural features in BPDCN may change our vision of this disease, leading to the designing of a new BPDCN cell model and to re-thinking the relations occurring between BPDCN and nervous system. The observed findings contribute to explaining the extreme tumor aggressiveness and also to propose novel therapeutic targets. In view of this, the identification, in this work of new po…

Cancer ResearchNeurogenesisNeoplasms. Tumors. Oncology. Including cancer and carcinogensMicroRNA Expression ProfilesequencingBiologySettore MED/08 - Anatomia PatologicaBPDCN MiRNA Network Neurogenesis SequencingBPDCNArticleChromatinGene expression profilingBPDCN; MiRNA; Network; Neurogenesis; SequencingneurogenesisOncologyDownregulation and upregulationmicroRNAnetworkCancer researchImmunohistochemistrySettore MED/05 - Patologia ClinicaNeurogenesiRC254-282ProgenitormiRNACancers
researchProduct